Search Results
Aug 04, 2025, 09:00 ET Minaris Advanced Therapies Opens New State-of-the-Art GMP Facility to Support Global Cell and Gene Therapy Growth
systems"The opening of this facility marks an important milestone in our mission to accelerate the development and manufacturing of transformative cell and gene therapies globally," said Dr. Orla Cloak, Chief Executive Officer of Minaris Advanced Therapies. "It enhances our European footprint and enhances
More news about: Minaris Advanced Therapies, LLC
Aug 04, 2025, 09:00 ET Minaris Advanced Therapies Opens New State-of-the-Art GMP Facility to Support Global Cell and Gene Therapy Growth
systems"The opening of this facility marks an important milestone in our mission to accelerate the development and manufacturing of transformative cell and gene therapies globally," said Dr. Orla Cloak, Chief Executive Officer of Minaris Advanced Therapies. "It enhances our European footprint and enhances
More news about: Minaris Advanced Therapies, LLC
Aug 04, 2025, 08:45 ET Contact The Gross Law Firm by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc.(SRPT)
during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: The Gross Law Firm
Aug 04, 2025, 08:30 ET Genprex Issues Stockholder Letter and Provides 2025 Corporate Update
collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex
More news about: Genprex, Inc.
Aug 04, 2025, 08:19 ET Jarlath Keating Joins as President of Solvias Group USA to Drive Growth and Innovation in Advanced Analytical Services
and Biotechnology Industry. Its expert team combines decades of experience with regulatory expertise across small molecules, biologics, and cell and gene therapies. Solvias offers end-to-end solutions from raw material testing to drug product release and API development for small molecules. Headquartered
More news about: Solvias
Aug 04, 2025, 05:33 ET MGI Tech Hands with Lincoln University to Revolutionize New Zealand Viticulture with Genomics
after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to
More news about: MGI Tech
Aug 04, 2025, 05:18 ET MGI Tech Hands with Lincoln University to Revolutionize New Zealand Viticulture with Genomics
after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to
More news about: MGI Tech
Aug 02, 2025, 16:11 ET AVANÇOS NA PESQUISA DA ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE DE 2025
pessoas.Caminhar e outras intervenções no estilo de vida podem beneficiar pessoas com o maior risco genético conhecido para a doença de Alzheimer, a variante do gene APOE4.Os primeiros resultados de estudos do "mundo real" de novos medicamentos amiloides direcionados à doença de Alzheimer confirmaram os
More news about: Alzheimer's Association
Aug 01, 2025, 14:30 ET Xtalks Announces its Life Science Webinar Calendar for August 2025
Upcoming free, educational webinars from Xtalks will feature topics on cell and gene therapy, clinical trials, commercialization & HEOR, drug discovery & development, healthcare, laboratory technology, medical device, patient recruitment & retention, pharma manufacturing & supply
More news about: Xtalks
Aug 01, 2025, 09:00 ET Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for Investors - Contact Levi & Korsinsky
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: Levi & Korsinsky, LLP
Jul 31, 2025, 17:31 ET KIT Inhibitors Market Growth: Key Trends and Future Projections in the 7MM Upto 2034 | DelveInsight
the development of highly selective inhibitors that can overcome resistance to first-generation therapies. For example, mutations in the KIT gene often lead to resistance against older drugs like imatinib, pushing the need for next-generation inhibitors with improved efficacy and tolerability.
More news about: DelveInsight Business Research, LLP
Jul 31, 2025, 13:08 ET AVANCÉES DE LA RECHERCHE LORS DE LA ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025
personnes âgées porteuses du gène de risque d'Alzheimer's connu sous le nom d'APOE4 ont tiré davantage de bénéfices cognitifs d'interventions non médicamenteuses telles que l'exercice, le régime alimentaire et l'entraînement cognitif que les personnes non porteuses de ce gène. Dans cette étude, la
More news about: Alzheimer's Association
Jul 31, 2025, 10:45 ET Contract Research Organization Market is Poised to Reach USD 122.2 Billion by 2032 | SkyQuest Technology Consulting
development industry. Moreover, two new growth opportunities in the contract research organization (CRO) market are the increasing demand for gene therapies and personalized medicine. These novel treatments would necessitate specialized clinical trials and regulatory knowledge, which might present
More news about: SkyQuest Technology
Jul 31, 2025, 10:30 ET Cell Culture Market worth US$50.69 billion by 2030 with 11.2% CAGR | MarketsandMarkets™
increasing focus on the advancement of the biopharmaceutical industry, high government investments & funding for R&D, and growing demand for cell and gene therapy. Request Sample Pages :
More news about: MarketsandMarkets
Jul 31, 2025, 10:15 ET Biopharmaceuticals Market is Estimated to Reach USD 948.6 Bilion by 2032 | SkyQuest Technology Consulting
biopharmaceutical industry is growing rapidly as a result of significant advancements in biotechnology and drug development. Due to developments in gene therapies, vaccines, monoclonal antibodies, and next-generation biologics, treatment paradigms are shifting in a variety of therapeutic areas. These
More news about: SkyQuest Technology
Jul 31, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
action] On May 27, 2025, Rocket issued a press release "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease." The press release disclosed that "[a] patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected
More news about: Pomerantz LLP
Jul 31, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG
dystrophy ("DMD"), a genetic disorder characterized by progressive muscle degeneration and weakness. DMD is caused by the mutation of the dystrophin gene, resulting in, inter alia, a limited production of the dystrophin protein, which in turn leads to DMD's clinical features. According to PepGen,
More news about: Pomerantz LLP
Jul 31, 2025, 09:06 ET Sarepta Therapeutics (SRPT) Tanks 36% After 3rd Patient Death, SRPT Securities Class Action Pending - Hagens Berman
different investigational gene therapy (SRP-9004) for limb-girdle muscular dystrophy. The company said it reported the death to the FDA on July 3, 2025. Separately, the FDA concurrently announced that it placed Sarepta investigational gene therapy clinical trials for
More news about: Hagens Berman Sobol Shapiro LLP
Jul 31, 2025, 08:45 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Therapeutics, Inc. Lawsuit - SRPT
during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: The Gross Law Firm
Jul 31, 2025, 08:30 ET Fresenius Medical Care's Third-Party Clinical Research Organization Frenova Announces Strategic Collaboration Advancing Genomics-Driven, Precision Kidney Disease Care
program and provided biospecimens, with a goal of reaching 50,000 participants over the next two years. The collaboration provides the analysis and gene sequencing necessary to extract the data's rich insights. "This large-scale whole genome sequencing initiative marks a pivotal milestone in our
More news about: Fresenius Medical Care Holdings, Inc.
Jul 31, 2025, 08:30 ET Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit
next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential
More news about: Actinium Pharmaceuticals, Inc.
Jul 31, 2025, 07:05 ET REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights
Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases,
More news about: REGENXBIO Inc.
Jul 31, 2025, 07:00 ET ScaleReady announces multiple G-Rex® Grants have been awarded to investigators at University of Minnesota's Center for Genome Engineering
unique cell and gene therapy drug products. The willingness of our Minnesota neighbors, Wilson Wolf and Bio-Techne, to allocate financial resources to our University of Minnesota cell and gene therapy (CGT) programs
More news about: Bio-Techne Corporation
Jul 31, 2025, 07:00 ET RESEARCH ADVANCES FROM THE 2025 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE
Alzheimer's Risk GenePeople with a higher genetic risk for Alzheimer's disease may benefit the most from healthy lifestyle interventions like walking, according to a decade of data from three large international studies. Older adults who carry the Alzheimer's risk gene known as APOE4 had
More news about: Alzheimer's Association
Jul 31, 2025, 07:00 ET RESEARCH ADVANCES FROM THE 2025 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE
Alzheimer's Risk GenePeople with a higher genetic risk for Alzheimer's disease may benefit the most from healthy lifestyle interventions like walking, according to a decade of data from three large international studies. Older adults who carry the Alzheimer's risk gene known as APOE4 had
More news about: Alzheimer's Association